For research use only. Not for therapeutic Use.
Osanetant is a tachykinin NK3 antagonist potentially for the treatment of schizophrenia.
| Catalog Number | M040719 |
| CAS Number | 160492-56-8 |
| Molecular Formula | C35H41Cl2N3O2 |
| Purity | ≥95% |
| Target | Neuronal Signaling |
| Storage | 4°C |
| IUPAC Name | N-[1-[3-[(3R)-1-benzoyl-3-(3,4-dichlorophenyl)piperidin-3-yl]propyl]-4-phenylpiperidin-4-yl]-N-methylacetamide |
| InChI | InChI=1S/C35H41Cl2N3O2/c1-27(41)38(2)35(29-13-7-4-8-14-29)19-23-39(24-20-35)21-9-17-34(30-15-16-31(36)32(37)25-30)18-10-22-40(26-34)33(42)28-11-5-3-6-12-28/h3-8,11-16,25H,9-10,17-24,26H2,1-2H3/t34-/m0/s1 |
| InChIKey | DZOJBGLFWINFBF-UMSFTDKQSA-N |
| SMILES | CC(=O)N(C)C1(CCN(CC1)CCCC2(CCCN(C2)C(=O)C3=CC=CC=C3)C4=CC(=C(C=C4)Cl)Cl)C5=CC=CC=C5 |
| Reference | </br>1:Identification of a critical residue in the transmembrane domain 2 of tachykinin neurokinin 3 receptor affecting the dissociation kinetics and antagonism mode of osanetant (SR 142801) and piperidine-based structures. Malherbe P, Kratzeisen C, Marcuz A, Zenner MT, Nettekoven MH, Ratni H, Wettstein JG, Bissantz C.J Med Chem. 2009 Nov 26;52(22):7103-12. doi: 10.1021/jm900948q. PMID: 19817444 </br>2:Me-talnetant and osanetant interact within overlapping but not identical binding pockets in the human tachykinin neurokinin 3 receptor transmembrane domains. Malherbe P, Bissantz C, Marcuz A, Kratzeisen C, Zenner MT, Wettstein JG, Ratni H, Riemer C, Spooren W.Mol Pharmacol. 2008 Jun;73(6):1736-50. doi: 10.1124/mol.107.042754. Epub 2008 Feb 28. PMID: 18308898 Free Article</br>3:Neurokinin-3 receptor-specific antagonists talnetant and osanetant show distinct mode of action in cellular Ca2+ mobilization but display similar binding kinetics and identical mechanism of binding in ligand cross-competition. Tian G, Wilkins D, Scott CW.Mol Pharmacol. 2007 Mar;71(3):902-11. Epub 2006 Dec 15. PMID: 17172464 Free Article</br>4:Randomized, double-blind study of SR142801 (Osanetant). A novel neurokinin-3 (NK3) receptor antagonist in panic disorder with pre- and posttreatment cholecystokinin tetrapeptide (CCK-4) challenges. Kronenberg G, Berger P, Tauber RF, Bandelow B, Henkel V, Heuser I.Pharmacopsychiatry. 2005 Jan;38(1):24-9. PMID: 15706463 </br>5:Osanetant Sanofi-Synthélabo. Kamali F.Curr Opin Investig Drugs. 2001 Jul;2(7):950-6. Review. PMID: 11757797 </br>6:A tachykinin NK3 receptor antagonist, SR 142801 (osanetant), prevents substance P-induced bronchial hyperreactivity in guinea-pigs. Daoui S, Cui YY, Lagente V, Emonds-Alt X, Advenier C.Pulm Pharmacol Ther. 1997 Oct-Dec;10(5-6):261-70. PMID: 9778489 |
